# tACS Modulates Speech and Cognitive Impairments in People With PD by Targeting the Medial Frontal Cortex

> **NCT07240272** · NA · COMPLETED · sponsor: **Ke Dong, MD** · enrollment: 28 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **OTHER:** 6Hz-tACS
- **OTHER:** Sham-tACS

## Key facts

- **NCT ID:** NCT07240272
- **Lead sponsor:** Ke Dong, MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07240272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07240272, "tACS Modulates Speech and Cognitive Impairments in People With PD by Targeting the Medial Frontal Cortex". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07240272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*